Arcalyst (rilonacept) is an anti-inflammatory therapy approved by the U.S. Food and Drug Administration (FDA) to treat adults and children 12 and older who live with cryopyrin-associated periodic syndromes, or CAPS. These syndromes include familial cold autoinflammatory syndrome (FCAS) and muscle-wells syndrome (MWS).
How Arcalyst works
Scleroderma is an autoimmune disease caused by an overactive immune system that mistakenly attacks healthy tissues, leading to scarring and thickening of the connective tissue in multiple tissues and organs.
Rilonacept, the active substance in Arcalyst, is an interleukin (IL) inhibitor. It works by attaching to interleukin-1 beta (IL-1β), an immune system protein that causes inflammation, and blocking its activity, which helps reduce inflammation and relieve the symptoms of scleroderma.
Arcalyst in clinical trials for systemic scleroderma
In the study, designed to provide preliminary data for a larger study, researchers used a four-gene biomarker of skin disease as the primary goal, in which a high biomarker score was equivalent to a high skin score and suggested higher disease severity.
Secondary outcomes included other measures of disease activity, including the modified Rodnan skin score (a measure of skin thickness), and health assessment questionnaire disability index (HAQ-DI), a questionnaire in which patients report the amount of difficulty experienced when performing certain activities.
The trial was completed in August 2017, but no results have been published yet.
Scleroderma News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.